This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
ESMO 2020
Presentations

Enfortumab vedotin | Urothelial Cancer | Abstract 2223
EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors

Enfortumab vedotin | Urothelial Cancer | Abstract 2065
Study EV-302: A 3-arm, open-label, randomized phase 3 study of enfortumab vedotin plus pembrolizumab and/or chemotherapy, versus chemotherapy alone, in untreated locally advanced or metastatic urothelial cancer

Tucatinib | Breast Cancer | Abstract 2073
Impact of tucatinib on progression free survival in patients with HER2+ metastatic breast cancer and brain metastases

Tucatinib | Colorectal Cancer | Abstract 2070
MOUNTAINEER: Open-Label, Phase 2 Study of Tucatinib Combined with Trastuzumab for HER2-Positive Metastatic Colorectal Cancer

Tucatinib | Breast Cancer | Abstract 2068
HER2CLIMB-02: A randomized, double-blind, phase 3 study of tucatinib or placebo with T DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer

Tucatinib | Research | Absract 3068
Physiologically Based Pharmacokinetic (PBPK) Modeling of the Central Nervous System (CNS) Pharmacokinetics of Tucatinib in Patients with Breast Cancer Brain Metastasis

Tisotumab vedotin | Ovarian Cancer | Abstract 2221
innovaTV 208: New Weekly Dosing Cohort in the Phase 2 Study of Tisotumab Vedotin in Platinum-Resistant Ovarian Cancer

Ladiratuzumab vedotin | Breast Cancer | Abstract 2075
SGNLVA-002: Single arm, open-label, phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer

Tucatinib | Breast Cancer | Abstract 2067
Impact of Tucatinib on Health-Related Quality of Life (HRQoL) in Patients with HER2+ Metastatic Breast Cancer (MBC) with and without Brain Metastases (BM)

Tisotumab vedotin | Cervical Cancer | Abstract 3435
Tisotumab vedotin (TV) in previously treated recurrent or metastatic cervical cancer (r/mCC): results from the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 study
Videos
Tucatinib | Breast Cancer | Abstract 2073
Impact of Tucatinib on Progression Free Survival in Patients with HER2+ Metastatic Breast Cancer and Brain Metastases
Tucatinib | Breast Cancer | Abstract 2067
Impact of Tucatinib on Health-Related Quality of Life (HRQoL) in Patients with HER2+ Metastatic Breast Cancer (MBC) with and without Brain Metastases (BM)
Tisotumab vedotin | Cervical Cancer | Abstract 3435
Tisotumab vedotin (TV) in previously treated recurrent or metastatic cervical cancer (r/mCC): results from the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 study
Enfortumab vedotin | Urothelial Cancer | Abstract 2223
EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors